Novel therapeutic monoclonal antibody targeting SP-R210 isoforms to prevent influenza disease progression and expedite resolution of comorbidities
Ended Project Grant Awarded Last action
- Award ID
- R41AI136294
- Recipient
-
Respana Therapeutics, Inc. UEI QGKNUK6SJUW4
- Awarding agency
-
National Institute of Allergy and Infectious Diseases
National Institutes of Health, Department of Health and Human Services
- Obligated
- $298,498
Award facts
- Assistance listing
- 93.855 Allergy and Infectious Diseases Research
- Completion date
- Originally
- Place of performance
- Pennsylvania, USA
Award details come from USAspending.gov.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Original award | $298,498 |
Quick answers
Who received award R41AI136294?
R41AI136294 was awarded to Respana Therapeutics, Inc. by National Institute of Allergy and Infectious Diseases (National Institutes of Health) on August 23, 2018.
How much is award R41AI136294 worth?
$298,498 has been obligated on R41AI136294.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award